The adoption of design fiction into design research has recently been expanding within the HCI community. Design fiction workshops have fruitfully facilitated users and researchers discussing and creating future technologies by exposing differing viewpoints. Yet, most scholarship focuses on the ostensibly successful outputs of these workshops. It remains unclear exactly what sort of interaction dynamics are instigated by design fiction in collaborative design. How might design fiction affect what we consider in design, and how is this reflected in the ensuing design? To fill this gap, our study examines design fictions across five workshops where diverse participants created futuristic autobiographies, a method to elicit values, and built diegetic prototypes both individually and collaboratively. We detail their design processes and unpack three kinds of soft conflicts that arose between participants and allowed them to bring up and discuss differing values regarding technology in society. Reflecting on our workshops, we discuss their implications on how one might employ design fiction in collaborative design.

Today's HTTP adaptive streaming applications are designed to provide high levels of Quality of Experience (QoE) across a wide range of network conditions. The adaptation logic in these applications typically needs an estimate of the future network bandwidth for quality decisions. This estimation, however, is challenging in cellular networks because of the inherent variability of bandwidth and latency due to factors like signal fading, variable load, and user mobility. In this paper, we exploit machine learning (ML) techniques on a range of radio channel metrics and throughput measurements from a commercial cellular network to improve the estimation accuracy and hence, streaming quality. We propose a novel summarization approach for input raw data samples. This approach reduces the 90th percentile of absolute prediction error from 54% to 13%. We evaluate our prediction engine in a trace-driven controlled lab environment using a popular Android video player (ExoPlayer) running on a stock mobile device and also validate it in the commercial cellular network. Our results show that the three tested adaptation algorithms register improvement across all QoE metrics when using prediction, with stall reduction up to 85% and bitrate switching reduction up to 40%, while maintaining or improving video quality. Finally, prediction improves the video QoE score by up to 33%.

Recent years have witnessed an explosion of multimedia traffic carried over the Internet. Video-on-demand and live streaming services are the most dominant services. To ensure growth, many streaming providers have invested considerable time and effort to keep pace with ever-increasing users' demand for better quality and stall abolition. HTTP adaptive streaming (HAS) algorithms are at the core of every major streaming provider service. Recent years have seen sustained development in HAS algorithms. Currently, to evaluate their proposed solutions, researchers need to create a framework and numerous state-of-the-art algorithms. Often, these frameworks lack flexibility and scalability, covering only a limited set of scenarios. To fill this gap, in this paper we propose DASHbed, a highly customizable real-time framework for testing HAS algorithms in a wireless environment. Due to its low memory requirement, DASHbed offers a means of running large-scale experiments with a hundred competing players. Finally, we supplement the proposed framework with a dataset consisting of results for five HAS algorithms tested in various evaluated scenarios. The dataset showcases the abilities of DASHbed and presents the adaptation metrics per segment in the generated content (such as switches, buffer-level, P. 1203.1 values, delivery rate, stall duration, etc.), which can be used as a baseline when researchers compare the output of their proposed algorithm against the state-of-the-art algorithms.

Summary In 2015, cholesterol deficiency (CD) was reported for the first time as a new recessive defect in Holstein cattle. After GWAS mapping and identification of a disease‐associated haplotype, a causative loss‐of‐function variant in APOB was identified. CD‐clinically affected APOB homozygotes showed poor development, intermittent diarrhea and hypocholesterolemia and, consequently, a limited life expectation. Herein, we present a collection of 18 cases clinically diagnosed as CD‐affected APOB heterozygotes. CD‐clinically affected heterozygotes show reduced cholesterol and triglyceride blood concentrations. The differences in total blood cholesterol and triglycerides between nine CD‐clinically affected and 36 non‐affected heterozygotes were significant. As only some APOB heterozygotes show the clinical CD phenotype, we assume that the penetrance is reduced in heterozygotes compared to the fully penetrant effect observed in homozygotes. We conclude that APOB‐associated CD represents most likely an incomplete dominant inherited metabolic disease with incomplete penetrance in heterozygotes.

Abstract Subjects (n=13) did 30 workouts with their left leg on an Inertial Exercise Trainer (IET), while their right leg served as an untreated control. Before and after the 30 workouts, they underwent isokinetic strength tests (knee and ankle extensors of both legs) whose peak torque (PT), time to PT (TTPT), and rate of torque development (RTD) values were each analyzed with 2(leg)×2(time)×3(velocity) analysis of variances (ANOVAs), with repeated measures per independent variable. Peak force (PF) and total work (TW) data were measured from each IET workout, and they represent time course strength changes produced by our exercise intervention. PF and TW values for the three IET exercises that comprised each workout were each analyzed with one-way ANOVAs with time as the independent variable. Results included significant ankle and knee extensor PT increases, whereby the left leg achieved higher values at posttesting, but there were no significant TTPT changes and a time effect for ankle extensor RTD. Our data show that PF and TW each had significant increases over time, with the latter exhibiting greater gains over the 30-workout intervention. Our results imply that the IET yields strength gains over time comparable to standard resistive exercise hardware.

Background: Right ventricular dysfunction (RVD) is a well-known predictor of early death in patients with acute pulmonary embolism and thus early identification of RVD is critical in the risk stratification or management of acute pulmonary embolism (PE). Aim of this study was to investigate a useful role of cardiac biomarker NTproBNP for predicting echocardiographic right ventricular dysfunction in patients with acute pulmonary embolism. Methods: A retrospective analysis was performed in 195 consecutive adult patients with pulmonary embolism from the Serbian University Pulmonary Embolism Registry (SUPER 2015-2019) created by six university clinics: Military Medical Academy (Belgrade), Institute of Pulmonary Diseases (Sremska Kamenica), Clinical Center (Nis), University Clinic Zvezdara, Clinical Center (Kragujevac) and University Clinical Centre of Republic of Srpska (Banja Luka). All patients were divided into RVD group and non-RVD group according to whether there was increase in systolic pressure in right ventricle (>40mmHg) on echocardiography. Odds ratios (OR) and 95% confidence intervals (CI) assessing the risk factors for RVD were assessed by multivariate logistic regression. The ability of the NT proBNP in predicting the RVD was described by the Receiving Operating Curves analysis. Results: The mean age is a strong predictor of echocardiographic RVD in patients with PE. The simple measurements of this cardiac biomarker could be helpful in clinical decision-making or risk stratification in patients with PE.

BACKGROUND This study examined the accuracy of cardiopulmonary exercise testing (CPET) on a treadmill (TM) and recumbent ergometry (RE) in the predicting coronary artery disease (CAD) severity and prognosis. METHODS Forty Caucasian subjects, mean age 63.5 ± 7.6, with significant coronary artery lesions (≥50%) were included. Within two months of coronary angiography, TM and RE CPET were performed on two visits 2-4 days apart and subsequently followed up to 32 ± 10 months. RESULTS Mean left ventricular ejection fraction was 56.7 ± 9.6%. TM CPET exhibited a higher occurrence of ST segment depression ≥ 1 mm (71.05% vs 28.95%, p = 0.04). Subjects with 1-2 stenotic coronary arteries (SCA) demonstrated a better CPET response compared to those with 3-SCA. ROC analysis revealed a high predictive value for the ventilation/carbon dioxide production (VE/VCO2) slope obtained on TM (area 0.84, p = 0.003, Sn 88.9%, Sp 72%) in distinguishing between 1 and 2-SCA and 3-SCA. Among all CPET parameters, work efficiency (∆VO2/∆WR) during RE predicted cumulative cardiac events (p < 0.01). CONCLUSIONS CPET parameters hold predictive value for CAD severity and prognosis. CPET on a TM appears to be more reliable in the quantification of CAD compared to RE.

Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1%), generic imatinib (up to -97.8%) and generic temozolomide (up to -80.7%). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer